More than 37 million Americans – close to one in ten – have diabetes. That’s a staggering number of individuals who are paying for (or having their insurance pay for) monthly doses of insulin, the drug needed to help regulate a patient’s blood sugar levels. Coincidentally insulin costs have more than tripled in the past twenty years, a result of the messy relationship between insurance and pharmaceutical companies.
In March of last year the U.S. House passed the Affordable Insulin Now Act, sponsored by U.S. Sen. Raphael Warnock, D-GA and carried in the House by U.S. Rep. Lucy McBath, D-GA, which capped insulin copays at $35 a month for American seniors on Medicare. The legislation was later folded into the Inflation Reduction Act, the massive (and controversial) budget reconciliation bill passed in August.
Please enter your User Name and Password to view the rest of this subscriber-only story or poll. If you are unable to login, your account may have expired. Please contact InsiderAdvantage if you have any problems.
